![Linda Stevens](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael P. Weiner | M | - |
Abbratech, Inc.
![]() Abbratech, Inc. BiotechnologyHealth Technology Abbratech, Inc. is a biotechnology company that focuses on precision antibodies. Abbratech is based in Branford, CT. The company offers services such as antigen and project design, recombinant antibody development, antibody optimization, and antibody production. Abbratech uses the best available in vivo and in vitro methods for antibody discovery and applies knowledge gained from the past 15 years of human genome sequencing and antibody engineering to produce high affinity and highly specific recombinant antibodies. The company was founded in 2020 by Michael P. Weiner, who has been the CEO since then. | 4 years |
Michael Egholm | M | 61 |
Abbratech, Inc.
![]() Abbratech, Inc. BiotechnologyHealth Technology Abbratech, Inc. is a biotechnology company that focuses on precision antibodies. Abbratech is based in Branford, CT. The company offers services such as antigen and project design, recombinant antibody development, antibody optimization, and antibody production. Abbratech uses the best available in vivo and in vitro methods for antibody discovery and applies knowledge gained from the past 15 years of human genome sequencing and antibody engineering to produce high affinity and highly specific recombinant antibodies. The company was founded in 2020 by Michael P. Weiner, who has been the CEO since then. | - |
Sean Mackay | M | 41 |
Abbratech, Inc.
![]() Abbratech, Inc. BiotechnologyHealth Technology Abbratech, Inc. is a biotechnology company that focuses on precision antibodies. Abbratech is based in Branford, CT. The company offers services such as antigen and project design, recombinant antibody development, antibody optimization, and antibody production. Abbratech uses the best available in vivo and in vitro methods for antibody discovery and applies knowledge gained from the past 15 years of human genome sequencing and antibody engineering to produce high affinity and highly specific recombinant antibodies. The company was founded in 2020 by Michael P. Weiner, who has been the CEO since then. | - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United States | 3 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Linda Stevens
- Personal Network